Real-world comparative effectiveness of tofacitinib, tumour necrosis factor inhibitors, and interleukin 17 inhibitors among patients with axial spondylarthritis and psoriatic arthritis First published 15/11/2024 Last updated 29/07/2025 EU PAS number:EUPAS1000000226 Study Ongoing